文献速递其他结缔组织病

进展为系统性硬化的预测因素:大型单中心队列中极早期系统性硬化诊断分析

Predictors of progression to systemic sclerosis: analysis of very early diagnosis of systemic sclerosis in a large single-centre cohort.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该单中心横断面分析纳入217例有雷诺现象且至少一项系统性硬化表现的患者,评估极早期系统性硬化(VEDOSS)特征组合对进展为系统性硬化的预测价值。中位随访4年,153例(70.5%)被分类为系统性硬化,69.3%的系统性硬化患者符合VEDOSS标准而末进展者仅6.3%。雷诺现象+肿胀手指+ANA阳性+甲襞毛细血管镜SD模式或系统性硬化特异性抗体(VEDOSS 2级)的比值比为19.52(95%CI 4.48, 85.06;P<0.001)。

要点

  • 217例雷诺现象伴至少一项系统性硬化表现者中,153例(70.5%)分类为系统性硬化。
  • VEDOSS 2级组合(雷诺现象+肿胀手指+ANA阳性+SD-NFC或特异性抗体)OR 19.52(95%CI 4.48, 85.06;P<0.001)。
  • 无雷诺现象外临床症状的组合与未进展相关:雷诺现象+SD-NFC OR 0.03(P<0.001)。

核心结论

  • 在无皮肤受累的雷诺现象且至少一项系统性硬化表现患者中,VEDOSS特征组合是中位随访4年进展为系统性硬化的最强预测因素。

研究设计与样本

  • 单中心横断面分析,纳入2010年至2019年在硬皮病门诊就诊的217例雷诺现象患者,均有系统性硬化特定临床表现或系统性硬化自身抗体或甲襞毛细血管镜SD模式(SD-NFC),无皮肤受累。
  • 评估VEDOSS表现及VEDOSS特征组合对进展为系统性硬化的预测价值。

主要发现

  • 217例中153例(70.5%)被分类为系统性硬化,其中65例(30%)在首次检查时即分类。
  • 系统性硬化患者中69.3%符合VEDOSS标准,而未进展为系统性硬化的患者中仅6.3%符合。
  • 与进展为系统性硬化最相关的组合为雷诺现象+肿胀手指+ANA阳性+SD-NFC和/或系统性硬化特异性抗体(VEDOSS 2级),OR 19.52(95%CI 4.48, 85.06;P<0.001)。
  • 雷诺现象+肿胀手指+ANA阳性(VEDOSS 1级;「警示信号」)的OR 15.45(P<0.001)。
  • 无雷诺现象外临床症状的组合与未进展相关:雷诺现象+SD-NFC的OR 0.03(P<0.001),雷诺现象+抗着丝点抗体+SD-NFC的OR 0.06(P=0.006)。

关键数值与推荐

  • VEDOSS 2级组合(雷诺现象+肿胀手指+ANA阳性+SD-NFC和/或系统性硬化特异性抗体)OR 19.52(95%CI 4.48, 85.06;P<0.001)。
  • VEDOSS 1级组合(雷诺现象+肿胀手指+ANA阳性)OR 15.45(P<0.001)。
  • 雷诺现象+SD-NFC组合OR 0.03(P<0.001),与未进展为系统性硬化相关。
  • 雷诺现象+抗着丝点抗体+SD-NFC组合OR 0.06(P=0.006),与未进展为系统性硬化相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study analysed the very early disease of SSc (VEDOSS) characteristics in a group of 217 patients with RP and at least one manifestation of SSc in search of predictors for the progression to SSc. METHODS: This was a cross-sectional single-centre analysis of patients presenting with RP with a specific SSc clinical manifestation or SSc autoantibody or SD pattern at nailfold capillaroscopy (SD-NFC), without skin involvement, who attended a scleroderma outpatient clinic between 2010 and 2019. The performance of VEDOSS and the importance of the combination of VEDOSS characteristics to predict the progression to SSc were evaluated. RESULTS: Among 217 patients, 153 (70.5%) were classified as SSc, including 65 (30%) in the first investigation; 69.3% of the SSc patients met VEDOSS criteria compared with 6.3% of patients who did not progress to SSc. The combinations most associated with progression to SSc were RP + puffy fingers (PF) + positive ANA + SD-NFC and/or SSc-specific antibody (VEDOSS level 2), with an odds ratio (OR) of 19.52 (95% CI 4.48, 85.06; P < 0.001) and RP + PF + positive ANA (VEDOSS level 1; 'red flags') (OR 15.45; P < 0.001), while combinations without non-RP clinical symptoms, as RP + SD-NFC (OR 0.03; P < 0.001) and RP + anticentromere + SD-NFC (OR 0.06; P = 0.006) were associated with non-progression to SSc. CONCLUSION: Among patients with RP with at least one manifestation of SSc, without skin involvement, combinations of VEDOSS characteristics were the strongest predictors of progression to SSc at a median follow-up of 4 years.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Siqueira VS, Helbingen MFS, Medeiros-Ribeiro AC, et al. Predictors of progression to systemic sclerosis: analysis of very early diagnosis of systemic sclerosis in a large single-centre cohort. Rheumatology (Oxford). 2022. PMID: 35020814. doi:10.1093/rheumatology/keac006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。